Baroreceptors as a target of device‐based neuromodulation in heart failure: Long‐term outcomes

European Journal of Heart FailureEarly View Invited Editorial Baroreceptors as a target of device-based neuromodulation in heart failure: Long-term outcomes Guido Grassi, Corresponding Author Guido Grassi [email protected] Clinica Medica, Department of Medicine and Surgery, University Milano-Bicocca, Milan, Italy Corresponding author. Clinica Medica, Università Milano-Bicocca, Via Pergolesi 33, 20052 Monza, Italy. Tel: +39 039 2333357, Email: [email protected]Search for more papers by this authorRaffaella Dell'Oro, Raffaella Dell'Oro Clinica Medica, Department of Medicine and Surgery, University Milano-Bicocca, Milan, ItalySearch for more papers by this authorFosca Quarti-Trevano, Fosca Quarti-Trevano Clinica Medica, Department of Medicine and Surgery, University Milano-Bicocca, Milan, ItalySearch for more papers by this author Guido Grassi, Corresponding Author Guido Grassi [email protected] Clinica Medica, Department of Medicine and Surgery, University Milano-Bicocca, Milan, Italy Corresponding author. Clinica Medica, Università Milano-Bicocca, Via Pergolesi 33, 20052 Monza, Italy. Tel: +39 039 2333357, Email: [email protected]Search for more papers by this authorRaffaella Dell'Oro, Raffaella Dell'Oro Clinica Medica, Department of Medicine and Surgery, University Milano-Bicocca, Milan, ItalySearch for more papers by this authorFosca Quarti-Trevano, Fosca Quarti-Trevano Clinica Medica, Department of Medicine and Surgery, University Milano-Bicocca, Milan, ItalySearch for more papers by this author First published: 25 April 2024 https://doi.org/10.1002/ejhf.3258 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.3232. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Starling EH. The Arris and Gale Lectures on some points in the pathology of heart disease. Lecture I. Lancet 1897; 149: 569–572. 10.1016/S0140-6736(00)64622-6 Google Scholar 2Grassi G, Mancia G, Esler MD. Central and peripheral sympathetic activation in heart failure. Cardiovasc Res 2022; 118: 1857–1871. https://doi.org/10.1093/cvr/cvab222 10.1093/cvr/cvab222 CASPubMedWeb of Science®Google Scholar 3Grassi G, Quarti-Trevano F, Esler MD. Sympathetic activation in congestive heart failure: An updated overview. Heart Fail Rev 2021; 26: 173–182. https://doi.org/10.1007/s10741-019-09901-2 10.1007/s10741-019-09901-2 PubMedWeb of Science®Google Scholar 4Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: A proof-of-concept study. Eur J Heart Fail 2014; 16: 977–983. https://doi.org/10.1002/ejhf.138 10.1002/ejhf.138 CASPubMedWeb of Science®Google Scholar 5Zile MR, Lindenfeld JA, Weaver FA, Zannad F, Galle E, Rogers T, et al. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes. Eur J Heart Fail. https://doi.org/10.1002/ejhf.3232 Published online ahead of print 12/04/24. 10.1002/ejhf.3232 Google Scholar 6Zile MR, Abraham WT, Weaver FA, Butter C, Ducharme A, Albach M, et al. Barorelex activation therapy for the treatment of heart failure with a reduced ejection fraction: Safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail 2015; 17: 1066–1074. https://doi.org/10.1002/ejhf.299 10.1002/ejhf.299 PubMedWeb of Science®Google Scholar 7Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015; 3: 487–496. https://doi.org/10.1016/j.jchf.2015.02.006 10.1016/j.jchf.2015.02.006 PubMedWeb of Science®Google Scholar 8Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol 2020; 76: 1–13. https://doi.org/10.1016/j.jacc.2020.05.015 10.1016/j.jacc.2020.05.015 CASPubMedWeb of Science®Google Scholar 9Coats AJS, Abraham WT, Zile MR, Lindenfeld JA, Weaver FA, Fudim M, et al. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: A patient level meta-analysis of randomized controlled trials. Eur J Heart Fail 2022; 24: 1665–1673. https://doi.org/10.1002/ejhf.2573 10.1002/ejhf.2573 CASPubMedWeb of Science®Google Scholar 10Doiron JE, Li Z, Yu X, LaPenna KB, Quiriarte H, Allerton TD, et al. Early renal denervation attenuates cardiac dysfunction in heart failure with preserved ejection fraction. J Am Heart Assoc 2024; 13:e032646. https://doi.org/10.1161/JAHA.123.032646 10.1161/JAHA.123.032646 PubMedGoogle Scholar 11Patel HC, Rosen SD, Hayward C, Vassiliou V, Smith GC, Wage RR, et al. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): A randomized controlled trial. Eur J Heart Fail 2016; 18: 703–712. https://doi.org/10.1002/ejhf.502 10.1002/ejhf.502 CASPubMedWeb of Science®Google Scholar 12Grassi G, Seravalle G, Vanoli J, Facchetti R, Spaziani D, Mancia G. Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure. Clin Res Cardiol 2023; 112: 59–67. https://doi.org/10.1007/s00392-022-02028-9 10.1007/s00392-022-02028-9 CASPubMedGoogle Scholar 13Fatima K, Butler J, Fonarow GC. Residual risk in heart failure and the need for simultaneous implementation and innovation. Eur J Heart Fail 2023; 25: 1477–1480. https://doi.org/10.1002/ejhf.3005 10.1002/ejhf.3005 PubMedGoogle Scholar 14Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens 2009; 27: 1509–1520. https://doi.org/10.1097/HJH.0b013e32832e9500 10.1097/HJH.0b013e32832e9500 CASPubMedWeb of Science®Google Scholar 15Grassi G. Sympathetic activation as a goal of antihypertensive treatment: From drugs to devices. J Hypertens 2023; 41: 1688–1695. https://doi.org/10.1097/HJH.0000000000003538 10.1097/HJH.0000000000003538 CASPubMedGoogle Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation